巴多司他(Baxdrostat) - 药物靶点：CYP11B2_在研适应症：醛固酮增多症，心脏衰竭，慢性肾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

CIN 107、CIN-107、RO-6836191

靶点

CYP11B2

作用方式

抑制剂

作用机制

CYP11B2 抑制剂(细胞色素P450家族成员11B2 抑制剂)

治疗领域

心血管疾病内分泌与代谢疾病泌尿生殖系统疾病

在研适应症

醛固酮增多症心脏衰竭慢性肾病+ [4]

非在研适应症

脊髓疾病

原研机构

CinCor Pharma, Inc.

在研机构

AstraZeneca PLC阿斯利康全球研发（中国）有限公司AstraZeneca AB

非在研机构

权益机构

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H25N3O2

InChIKeyVDEUDSRUMNAXJG-LJQANCHMSA-N

CAS号1428652-17-8

关联

27

项与巴多司他相关的临床试验

NCT07007793

/ Recruiting临床3期

A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism

This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and unsuppression of Plasma Renin Activity (PRA) in approximately 180 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics.
Baxdrostat (or placebo) will be administered once daily, up-titrated after 2 weeks to based on clinical response and tolerability. The study is planned to be conducted globally in approximately 90 study centres and approximately 12 countries.

开始日期2025-08-07

申办/合作机构

AstraZeneca PLC

CTIS2024-514506-32-00

/ Recruiting临床3期

A Phase III, Randomised, Double-Blind, Placebo-controlled, Event driven Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death in Participants with Increased Risk of Developing Heart Failure - D6973C00001

开始日期2025-05-12

申办/合作机构

AstraZeneca AB

CTRI/2025/04/085048

/ Not yet recruiting临床3期

A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with DapagliflozinAlone on the Risk of Incident Heart Failure and Cardiovascular Death in Participants with Increased Risk of Developing Heart Failure BaxDuo Prevent HF - BaxDuo Prevent HF

开始日期2025-04-28

申办/合作机构

AstraZeneca AB

[+1]

100 项与巴多司他相关的临床结果

登录后查看更多信息

100 项与巴多司他相关的转化医学

登录后查看更多信息

100 项与巴多司他相关的专利（医药）

登录后查看更多信息

33

项与巴多司他相关的文献（医药）

2025-10-09·NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension

Article

作者: Perl, Shira ; Azizi, Michel ; Dwyer, Jamie P. ; Williams, Bryan ; Wittes, Janet ; Brown, Jenifer M. ; Fronczek, Jakub ; Wang, Ji-Guang ; Shibata, Hirotaka ; Wilderäng, Ulrica ; Jones, Erika S.W. ; Olsson, Daniel S. ; Flack, John M.

BACKGROUND:

Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood pressure of patients with uncontrolled or resistant hypertension.

METHODS:

In this phase 3, multinational, double-blind, randomized, placebo-controlled trial, we recruited patients with a seated systolic blood pressure of between 140 mm Hg and less than 170 mm Hg despite the receipt of stable treatment with two antihypertensive medications (uncontrolled hypertension) or three or more such medications (resistant hypertension), including a diuretic. After a 2-week placebo run-in period, we randomly assigned patients with a seated systolic blood pressure of 135 mm Hg or more in a 1:1:1 ratio to receive baxdrostat at a dose of 1 mg, baxdrostat at a dose of 2 mg, or placebo once daily for 12 weeks. The primary end point was the change in seated systolic blood pressure from baseline to week 12.

RESULTS:

A total of 796 patients underwent randomization and 794 received 1-mg baxdrostat (264 patients), 2-mg baxdrostat (266 patients), or placebo (264 patients) in addition to background therapy. At 12 weeks, the change from baseline in the least-squares mean seated systolic blood pressure was -14.5 mm Hg (95% confidence interval [CI], -16.5 to -12.5) with 1-mg baxdrostat, -15.7 mm Hg (95% CI, -17.6 to -13.7) with 2-mg baxdrostat, and -5.8 mm Hg (95% CI, -7.9 to -3.8) with placebo. The estimated difference from placebo (placebo-corrected difference) was -8.7 mm Hg (95% CI, -11.5 to -5.8) with 1-mg baxdrostat and -9.8 mm Hg (95% CI, -12.6 to -7.0) with 2-mg baxdrostat (P<0.001 for both comparisons). A potassium level of more than 6.0 mmol per liter was reported in 6 patients (2.3%) with 1-mg baxdrostat, in 8 patients (3.0%) with 2-mg baxdrostat, and in 1 patient (0.4%) with placebo.

CONCLUSIONS:

Among patients with uncontrolled or resistant hypertension, the addition of baxdrostat to background therapy resulted in a significantly lower seated systolic blood pressure at 12 weeks than placebo. (Funded by AstraZeneca and others; BaxHTN ClinicalTrials.gov number, NCT06034743.).

2025-08-01·JOURNAL OF HYPERTENSION

Breaking down resistance: novel aldosterone synthase inhibitors in the management of resistant hypertension

Review

作者: George, Jacob ; Kocherry, Cyril ; Eddison Chung Hung, Chai

This review aims to evaluate the impact of novel aldosterone synthase inhibitors, the first new class of antihypertensives in more than 20 years, on the management of resistant hypertension. We highlight the problem of resistant hypertension in clinical practice and describe the challenging history and development of aldosterone synthase inhibitors. The review highlights clinical trial evidence to-date for all agents in this class, with a key focus on the two most mature agents baxdrostat and lorundrostat which are currently in pivotal Phase 3 trials. Both agents have demonstrated significant dose-dependent reductions in blood pressure, particularly in patients with resistant hypertension and crucially, with a minimal impact on cortisol levels. They have also shown promise with marked blood pressure reductions in patients with varying physiological profiles and few adverse events at optimised doses. However, as would be expected, both drugs are associated with increases in serum potassium levels, necessitating careful monitoring.

2025-08-01·BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Blood Pressure–Lowering Effects of Aldosterone Synthase Inhibitors—A Systematic Review

Review

作者: Buus, Niels Henrik ; Rasmussen, Anders Almskou ; Simonsen, Ulf ; Nordestgaard, Ketil Lehm

ABSTRACT:

Excess aldosterone production contributes to the development of hypertension and results in fibrosis with dysfunction of the heart, vasculature and kidneys. Consequently, new agents have been developed to reduce endogenous aldosterone synthesis. The primary objective of this systematic review is to describe the BP‐lowering effects of aldosterone synthase inhibitors (ASIs) in hypertensive patients and, secondly, to describe their potential renal protective effects and possible influence on cortisol production and plasma potassium. We searched PubMed, Embase and ClinicalTrials.gov and included randomized controlled and clinical trials according to PICO using the review tool Covidence. Thirteen studies were included and all demonstrated BP reduction through ASI treatment. Among patients with apparent resistant hypertension, the placebo‐corrected reductions in seated systolic BP were 11.0 mmHg for baxdrostat and 9.6 mmHg for lorundrostat. A significant suppression of cortisol production was found for LCI699 (osilodrostat) but not for baxdrostat, lorundrostat, BI 690517 (vicadrostat) or dexfadrostat. Studies on BI 690517 showed a reduction in urine–albumin–creatinine ratio, indicating renal protection. ASIs may increase potassium levels. We conclude that ASIs have promising BP‐lowering effects with very limited effects on cortisol production and offer reno‐protective effects in chronic kidney disease. Studies on hypertensive target organ damage and cardiovascular outcomes are, however, lacking.

199

项与巴多司他相关的新闻（医药）

2025-10-10

·Pharmaceutical Technology

AstraZeneca sets $4.5bn Virginia API plant construction in motion

AstraZeneca has broken ground on its $4.5bn US API manufacturing plant in Charlottesville, Virginia. Image credit: rarrarorro via ShutterStock.com. AstraZeneca has commenced construction of its $4.5bn active pharmaceutical ingredient (API) manufacturing facility in Virginia. The site, which is located near Charlottesville, will produce APIs for medicines across its cardiovascular, obesity, oncology and metabolic disease portfolio. This includes drugs from the company’s mid-to-late-stage pipeline – namely its Eccogene-partnered glucagon-like peptide-1 receptor agonist (GLP-1RA) pill, AZD5004/ ECC-5004, as well as hypertension med baxdrostat and low-density lipoprotein (LDL) degrader, laroprovstat. On top of the $4bn originally pledged for the site’s construction, AstraZeneca announced it would pour an extra $500m into the Virginia facility on 9 October, facilitating the construction of extra production capacity for its cancer portfolio. The site will now also be used to manufacture antibody drug conjugates (ADCs), which the big pharma considers to be a core part of its oncology R&D strategy due to the drug class’s potential to become the “ backbone of cancer care ”. Though AstraZeneca did not specify which ADCs it will produce at the Virginia site, the company has received the regulatory nod for two of its products in this drug class. This includes blockbuster seller Enhertu (trastuzumab deruxtecan), which GlobalData analysts forecast will rake in $14.3bn for the pharma in 2031. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence GlobalData is the parent company of Pharmaceutical Technology . The other asset in the company’s growing ADC portfolio is Datroway (datopotamab deruxtecan), which was recently granted accelerated approval in non-small cell lung cancer (NSCLC). This drug may also take AstraZeneca closer to its goal of putting ADCs in the oncology limelight, as the Phase III TROPION-Breast02 trial found that Datroway outperformed chemotherapy in first-line breast cancer for immunotherapy-ineligible patients. Virginia’s growing pharma presence AstraZeneca’s Virginia facility will house 600 full-time roles, while 3,000 jobs will be created during the build. If all goes to plan, the company anticipates the site will open within the next four-to-five years. According to the UK-Swedish pharma giant, this facility will be the “cornerstone” of its $50bn US investment , which the company made amid 100% tariff threats on branded drug imports from the Trump administration. AstraZeneca’s CEO, Pascal Soriot, also noted that this investment is the “largest in the company’s history,” and will work to “strengthen America’s national security and health sovereignty”. The pharma’s choice to place operations in Virginia closely follows Eli Lilly’s $5bn manufacturing investment into the area, which will see the company build a biconjugate and monoclonal antibody (mAb) production facility in Goochland County. AstraZeneca and Eli Lilly will also join rival Merck in the region, which expanded capacity at its Elkton site in 2022 to bolster supplies of its human papillomavirus (HPV) vaccine, Gardasil. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

临床3期上市批准疫苗临床结果免疫疗法

2025-10-09

·EndPoints

AstraZeneca breaks ground on Virginia plant after Trump warns drugmakers to build or face tariffs

AstraZeneca is breaking ground on a multibillion-dollar API facility in Albemarle County, VA, making it the latest company to start building after President Donald Trump threatened 100% tariffs on drugmakers not starting construction in the US. The original value of the facility was $4 billion, but the company said Thursday it was increasing its investment to $4.5 billion, according to a press release. The build is part of AstraZeneca’s $50 billion pledge to the US, which it announced in July. The Virginia site will manufacture drug substances for AstraZeneca’s metabolic portfolio, including for its oral GLP-1 drug baxdrostat and its oral PCSK9 inhibitor. It will also house manufacturing for AstraZeneca’s antibody drug conjugates. The facility will be operational in the next four to five years and will create 600 new jobs, the company said in the release. Late last month, Trump warned in a social media post that starting Oct. 1, companies would face a 100% tariff on branded pharma products unless they are building manufacturing plants in the US. Yet, on Oct. 1, the White House confirmed to Endpoints that the levies will be delayed as they are still in preparation stages. Hello, Patricia Hopkins! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Patricia Hopkins! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Patricia Hopkins! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Patricia Hopkins! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Patricia Hopkins! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Patricia Hopkins! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Patricia Hopkins! You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Hello, Patricia Hopkins. You’re an essential part of the biopharma world. Share your voice on this subscriber Pulse Survey to help shape our understanding of the industry. Results will be anonymous. Since Trump’s announcement, several companies have issued press releases touting construction in the US. AbbVie announced it has started building two separate factories: an API facility in North Chicago, IL, and a $70 million expansion of its Worcester, MA, biologics site. Precision Biologics also started construction on a site in Las Vegas. Since Trump first threatened tariffs in February, drugmakers have pledged a total of over $320 billion to the US for biopharma manufacturing. But many companies are still scrambling to understand the details of Trump’s warnings, with their lawyers at a loss on how to advise what “breaking ground” means and who gets to decide if a company has started construction. While Trump pushes for more manufacturing in the US, drugmakers have been delaying or pulling out of new builds in the UK, over concerns that the UK government isn’t investing enough in the sector. The UK is in discussions with the Trump administration to pay up to 25% more for drugs in a move to appease biopharma companies. “If you are watching us from another country. Please do your part. If not, we will be happy to welcome your businesses to our country, which is what we’re witnessing today,” Mehmet Oz, administrator for the Centers for Medicare & Medicaid Services, said Thursday during the groundbreaking ceremony. The White House told Endpoints last week that pending pharma tariffs will apply to companies that aren’t onshoring their manufacturing to the US, as well as those that don’t participate in Trump’s “most favored nation” pricing plan. Pfizer was the first drugmaker to ink a deal with the Trump administration, agreeing to use MFN prices for new medicines in exchange for a three-year tariff exemption. Trump said last week that other companies are coming in to make similar deals. Editor’s Note: This story was updated with more details from AstraZeneca’s press release and groundbreaking ceremony.

2025-10-09

·汇聚南药

重磅创新药获突破！预计年销售额超50亿美元

10月7日阿斯利康宣布的重磅消息，为全球数亿高血压患者带来曙光 —— 其在研药物 baxdrostat的后期临床试验圆满达成主要目标，在难治性高血压患者中实现血压显著降低。阿斯利康计划将在年底前递交baxdrostat的审批，并预计该药物的年销售额最高将超过50亿美元。资料显示，Baxdrostat是一种靶向醛固酮合成酶(ALDOS，由CYP11B2基因编码)的潜在first-in-class、高选择性、强效口服小分子抑制剂。人体中，醛固酮对维持水盐平衡起着关键作用，但当醛固酮水平失调时，就会导致血压升高。而肾素-血管紧张素-醛固酮系统(RAAS)是调控醛固酮水平的重要系统，以往大部分降压药物主要作用于RAAS系统，但存在一定局限性。Baxdrostat突破了RAAS系统的桎梏，直接作用于醛固酮合成的关键环节，从根源上解决约25%高血压患者的致病问题。 Baxdrostat的出现，不仅仅是一种新药的诞生，更是高血压治疗领域的一次治疗范式的重大迁移。该药物从根源上解决问题，通过抑制醛固酮合成酶，实现醛固酮“源头截流”。这种治疗方式能够更准确地针对醛固酮失调这一关键致病因素，为患者提供更有效的治疗。尤其是对于那些存在肾损伤或心衰的患者，醛固酮的过度分泌会进一步加重病情，Baxdrostat的应用为他们开辟了新的治疗路径，有望延缓疾病的进展，提高患者的生活质量和生存率。据悉，该药物正在临床研究中的其他适应症还包括慢性肾病和预防心力衰竭。阿斯利康对该药年销售额超 50 亿美元的预期，植根于庞大的患者基数与多元适应症拓展。有数据统计，全球大概有13亿高血压患者，其中差不多一半都没得到有效控制。数据还显示，在中国，高血压患病率超过27%，患病人数大约有2.45亿，而且越来越多年轻人也被高血压盯上了，这也促使我国药企掀起一场创新突围战。国产创新药已实现从 "仿制改良" 到 "源头创新" 的质变。如信立泰1类创新降压新药信超妥于今年6月获批上市，该药物是我国自主研发、头个获批上市的国产ARNI(血管紧张素受体脑啡肽酶抑制剂)类降压新药。信超妥的上市，不仅为中国数亿高血压患者提供了全新的、更优效的治疗选择。再如恒瑞医药在创新研发领域取得重大突破，其自主研发的1类新药SHR-1209Ⅲ期临床试验数据显示，其降压效果优于传统ARB类药物，24小时动态血压达标率提升15个百分点，同时具有明确的心肾保护作用。此外，恒瑞医药布局的固定剂量复方制剂研发管线中，有3个品种已进入临床Ⅲ期，预计2026年陆续上市。业内表示，新药物与新技术正在构建更强大的防治体系。从 baxdrostat 的国际突破到国产新药的集群崛起，高血压治疗正进入 "机制精准化、给药长效化、疗效多元化" 的新时代。随着更多原创成果落地，高血压患者将获得更多新的治疗选择。喜欢我们文章的朋友点个“在看”和“赞”吧，不然微信推送规则改变，有可能每天都会错过我们哦~ 免责声明 “汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。信息来源：制药网往期推荐本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。

临床3期上市批准申请上市临床2期

100 项与巴多司他相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
醛固酮增多症	临床3期	美国	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	中国	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	日本	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	澳大利亚	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	加拿大	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	法国	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	德国	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	印度	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	意大利	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	西班牙	AstraZeneca PLC	2025-08-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06034743 (BaxHTN, Pubmed \| N Engl J Med)	临床3期	难治性高血压	794	Baxdrostat 1 mg	顧廠衊簾構遞憲鑰獵壓(繭壓艱網窪鬱網窪構襯) = 鬱鏇範襯網鹽製築醖構蓋鹹積觸築齋鹽餘簾鹹 (鏇齋選窪窪網蓋範築獵, -16.5 ~ -12.5) 更多	积极	2025-10-09
				Baxdrostat 2 mg	顧廠衊簾構遞憲鑰獵壓(繭壓艱網窪鬱網窪構襯) = 蓋鏇窪築窪衊鏇獵鹹鹹蓋鹹積觸築齋鹽餘簾鹹 (鏇齋選窪窪網蓋範築獵, -17.6 ~ -13.7)
NCT06168409 (Bax24, Company_Website) 人工标引	临床3期	难治性高血压	-	Baxdrostat (2mg) + standard of care	範製艱夢願鹽窪鹽壓簾(鏇鏇襯鬱艱簾襯廠鑰夢) = Baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average SBP compared with placebo at 12 weeks. Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events. 淵顧鏇積廠窪觸網網鏇 (鹽醖積鹹觸憲淵襯積顧 ) 达到	积极	2025-10-07
				Placebo + standard of care
NCT05432167 \| NCT06677060 \| NCT06168409 \| NCT06742723 \| NCT06268873 (Pubmed \| J Am Soc Nephrol)	临床2期	-	195	Baxdrostat low-dose (LD; 0.5 mg up-titrated to 1 mg)	淵繭築獵範艱鑰獵構願(窪顧構鬱襯顧鬱鏇齋選) = 蓋憲範鑰衊憲鹽蓋衊築鑰餘顧鬱餘壓選繭壓鹽 (膚鬱膚壓遞齋襯繭膚製, −15.1 ~ −2.9)	积极	2025-09-06
				Baxdrostat high-dose (HD; 2 mg up-titrated to 4 mg)	淵繭築獵範艱鑰獵構願(窪顧構鬱襯顧鬱鏇齋選) = 遞選鬱壓積壓簾廠餘餘鑰餘顧鬱餘壓選繭壓鹽 (膚鬱膚壓遞齋襯繭膚製, −13.2 ~ −1.2)
NCT06034743 (BaxHTN, N Engl J Med \| Company_Website) 人工标引	临床3期	高血压	796	Baxdrostat 1 mg	鬱鹽鏇膚積顧餘選獵夢(膚鑰範獵糧齋襯遞積壓) = 範築窪齋餘蓋壓顧窪膚獵鬱遞蓋鏇積膚壓窪餘 (鏇積壓衊選憲築窪顧壓, -16.5 ~ -12.5)	积极	2025-08-30
				Baxdrostat 2 mg	鬱鹽鏇膚積顧餘選獵夢(膚鑰範獵糧齋襯遞積壓) = 獵鹹窪願遞膚齋鑰襯憲獵鬱遞蓋鏇積膚壓窪餘 (鏇積壓衊選憲築窪顧壓, -17.6 ~ -13.7)
NCT06034743 (BaxHTN, Company_Website) 人工标引	临床3期	高血压	796	Baxdrostat 1 mg	構鑰夢鬱蓋選糧顧願壓(襯鏇齋膚糧淵積鹽膚膚) = baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks 顧窪齋膚範糧淵選壓願 (憲壓遞醖遞簾築願醖範 ) 达到更多	积极	2025-07-14
				Baxdrostat 2 mg
NCT04605549 (SPARK, N Engl J Med \| Pubmed) 人工标引	临床2期	醛固酮增多症	15	Baxdrostat	憲繭壓鹹簾壓餘鏇餘餘(窪鏇鏇鬱壓構齋範艱廠) = 壓遞糧餘積艱憲遞淵襯醖襯壓鹹簾獵築憲築餘 (醖選積憲壓蓋顧淵窪壓, 9.0) 更多	积极	2025-07-13
NCT05432167 (CTgov)	临床2期	高血压 \| 慢性肾病	195	Placebo	窪遞鹽築醖衊範觸遞襯(鏇襯糧襯鬱顧齋襯憲築) = 艱齋餘艱鹹鹽鬱廠顧鑰選遞鑰壓築鏇鬱製鹹築 (壓鏇範築齋積糧壓憲夢, 2.231) 更多	-	2025-05-20
NCT05459688 (CTgov)	临床2期	高血压	175	CIN-107	製範廠簾積選淵繭鬱夢 = 鏇蓋獵餘繭構襯淵鏇襯積鹹齋艱醖壓艱範獵鹽 (憲範願選鏇繭獵簾窪鏇, 遞壓膚築觸築糧鑰艱齋 ~ 蓋獵鏇壓鏇鑰壓窪獵鏇) 更多	-	2024-12-16
NCT05137002 (HALO, CTgov)	临床2期	高血压	249	Placebo (Placebo)	構鏇醖網鑰範襯窪夢網(範醖餘膚襯鬱製遞顧淵) = 蓋鹹觸願憲鹽蓋鬱襯製築窪壓鬱膚構窪製鹽淵 (衊醖願鬱廠顧衊鏇網廠, 1.58) 更多	-	2023-08-01
				CIN-107 (CIN-107 0.5 mg)	構鏇醖網鑰範襯窪夢網(範醖餘膚襯鬱製遞顧淵) = 網鏇鹽顧醖憲鑰築積鏇築窪壓鬱膚構窪製鹽淵 (衊醖願鬱廠顧衊鏇網廠, 1.63) 更多
NCT04519658 (BrigHTN, Pubmed \| N Engl J Med)	临床2期	难治性高血压	248	Baxdrostat 0.5 mg	願憲膚範構構製選構選(築繭願餘壓艱蓋顧淵獵) = 艱醖鏇壓積獵製觸鬱廠鬱廠蓋淵範艱顧積遞鹽 (獵艱蓋鑰憲鹽選觸廠鹹 )	积极	2023-02-02
				Baxdrostat 1 mg	願憲膚範構構製選構選(築繭願餘壓艱蓋顧淵獵) = 築憲艱夢積壓蓋窪選蓋鬱廠蓋淵範艱顧積遞鹽 (獵艱蓋鑰憲鹽選觸廠鹹 )